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Disturbances in complement recognition and control in human disease – An editorial to a special
issue on “Complement Regulation”
The current issue of Seminars in Immunology is devoted to com-
plement dysregulation and its role in human disease. The various arti-
cles in this issue will address key events in the initial complement re-
cognition and regulatory steps and explore the role of complement in
glomerulonephritis, pregnancy disorders, rheumatic diseases and
during development and disease of the central nervous system. The
authors of these special articles have done their best to provide up-
dated, yet compact, summaries of relevant research in these topics.
Complement recognizes its targets with the help of key recognition
molecules, like C1q of the classical pathway or ficolins and mannose-
binding lectin in the lectin pathway. Berhane Ghebrehiwet together with
his colleagues provides a comprehensive and specific description of the
most exciting receptor for C1q, that for the globular domains of C1q,
gC1qR. This receptor appears to have a broad range of ligands and func-
tions, to an extent that seems to exceed even that of C1q itself, the no-
toriously polyspecific complement recognition molecule. Despite the fact
that there are other C1q receptors, gC1qR seems to attract interest as a
“mystery molecule”. Many research groups from different fields have
come across with gC1qR in unbiased analyses. Thus, uncertainty still exists
as to the true nature of the receptor. This is despite the fact that its
structure and the main ligand, i.e. C1q, is known. The other ligands have
been described to include many coagulation and kinin system proteins.
Functionally, in addition to the complement system gC1qR may thus play
a role in coagulation and in generating bradykinin, a mediator of edema,
pain and inflammation. The paper by Ghebrehiwet et al provides also
some original data to indicate different interactions of the gC1qR receptor.
Intriguingly, the authors suggest effects of gC1qR on metabolism, mi-
tochondria, various types of cells, like endothelial cells and lymphocytes,
and finally on infectious microorganisms and cancer cells. How can a
single receptor be involved in so many activities? Arguments and ex-
planations can be found in this authoritative and comprehensive review.
The complement system has been considered as complicated by many.
However, the complexity of the system does not mean that it would not be
important. Quite the contrary – many apparently redundant ways of getting
activated or regulated only are the proof of the importance of the system.
An elegant, additional way of regulation of the complement system is de-
scribed by Cserhalmi, Józsi and colleagues. They show how the main
regulator of the key activation step in the amplification pathway is itself
regulated. It is only relatively recently that a family of complement factor
H-related proteins (FHRs) have been found to influence in an opposing way
the most important complement regulator factor H. The basic new concept
is that FHRs are mostly devoid of their own complement regulatory activity
but they can compete with factor H for binding to the C3d part of C3b, the
main effector molecule of complement, and in some cases also to the
surface polyanion targets. The paper tells potential reasons why this kind of
activity would have developed during evolution. It also describes me-
chanisms how abnormal FHRs, generated by genetic abnormalities in an
unstable region of the human genome, can have excessive activities leading
to diseases, like C3 glomerulonephritis. This is despite the fact that, except
for FHR1, the concentrations of FHRs are relatively low in circulation. They
can be significantly higher at local sites, though, which may mean yet
another level of regulation. Also, deletions in the genes, especially the
common FHR3-1 deletion, can have a predisposing effect on disease, via
generation of autoantibodies against factor H. This seems to be one of the
best examples of how tolerance to an endogenous molecule can be de-
pendent on other molecules, and how the tolerance can be lost. Because of
their apparent importance, research on FHRs is currently very active. For
more discussion on this very exciting topic and the current understanding,
please, turn a few pages and have a look.
Kidneys have classically been known to be the target for complement
attack. This is because of physiological reasons, abundant blood flow, high
filtration rate and direct contact of blood to the basement membranes in
the kidney glomeruli. Kaartinen et al describe in their article the role of
complement dysregulation in various forms of glomerulonephritis, all
characterized by inflammation and damage in kidney glomeruli. A tre-
mendous progress has been made recently in understanding the patho-
physiology of some of the diseases in this category. A general lesson has
been that the same disease outcome can take place because of multiple
different reasons, genetic mutations in different molecules, autoimmunity
or microbial infections. Usually, the common denominator for these dis-
eases is dysregulation of complement and its consequent overactivation or
misdirected attack against autologous tissues, usually endothelial cells,
blood cells or the glomerular basement membrane (GBM). For example, for
the rare Dense Deposit Disease (DDD), it is now well understood that
overactivation of complement in the fluid phase and consequent deposition
of C3b on the GBM is the main problem. This can be due to an autoanti-
body (called C3 nephritic factor) against the C3 convertase enzyme, C3bBb,
or against factor H N-terminus or mutation or deficiency of factor H itself.
In some other diseases, like IgA nephropathy and C3 glomerulonephritis, a
lot is known, but the full picture is not yet clear. As a very useful lesson, the
article describes differences in the pathophysiological processes of different
diseases, where complement is dysfunctional. The various forms of glo-
merulonephritis have taught us how different kinds of complement ab-
normalities can lead to distinctly different types of diseases. In addition, the
article takes a clinical point of view to the glomerular diseases, where the
nephrologists have various options for treatment. What is vital in choosing
the treatment strategy, is to have as good understanding of the disease
pathophysiology and of the causative factors as possible.
In early life, already at the embryo stage, a challenging contact between
the blastomere with only few cells and the maternal complement system
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takes place. Under normal circumstances the embryo is well protected
against complement attack by expressing complement regulators or by
being able to bind factor H. Infertility is common, but practically we don’t
know anything about the role of complement in this condition, which thus
remains a challenge for future studies. Once pregnancy gets initiated the
challenges continue, not least because the fetoplacental unit represents an
“allograft” with partially different tissue antigens and polymorphic variants
compared to the maternal tissues or molecules. Therefore, not surprisingly,
and despite the maternal immunological adaptation to the situation, there
are risks to the pregnancy. The activities and regulation of the complement
system during pregnancy and their potential abnormalities are discussed by
Laura Teirilä, Inkeri Lokki and colleagues. One of the most common
pregnancy complications is preeclampsia, where the pregnant woman’s
blood pressure increases and there is proteinuria suggesting a vascular
problem. The nature of the problem and the fact that the condition is
usually cured by delivery suggest that there is an overload of material re-
leased from the placenta to the maternal circulation. By being “only” a
temporary organ, the placenta is somewhat fragile and has a continuum of
surface epithelium, the syncytiotrophoblast, surrounding its villi, which are
in direct contact with the maternal blood. The article discusses recent ob-
servations about the role of complement in pregnancy, its deficiencies and
associating genetic variants that can a provide clues to the underlying
pathogenetic mechanisms. Apparently, multiple mechanisms operate to
maintain tolerance to the fetus during pregnancy and to clear any potential
microparticles released from placenta. Obviously, pregnancy can be a
precipitating factor for diseases like lupus or hemolytic uremic syndrome
(HUS), which have a strong underlying genetic predispositdelivery suggest
that there is an overload of material released from the placenta to the
maternal circulation. By being “only” a temporary organ, the placenta is
somewhat fragile and has a continuum of surface epithelium, the syncy-
tiotrophoblast, surrounding its villi, which are in direct contact with the
maternal blood. The article discusses recent observations about the role of
complement in pregnancy, its deficiencies and associating genetic variants
that can a provide clues to the underlying pathogenetic mechanisms.
Apparently, multiple mechanisms operate to maintain tolerance to the fetus
during pregnancy and to clear any potential microparticles released from
placenta. Obviously, pregnancy can be a precipitating factor for diseases
like lupus or hemolytic uremic syndrome (HUS), which have a strong un-
derlying genetic predisposition. In addition, mutations in distinct comple-
ment factors, regulators or receptors could be involved. These could pre-
dispose to impaired clearance, inflammation or manifestations of
intolerance. Indirectly the effects would be reflected in the maternal vas-
culature and especially in the kidneys. One of the best markers of pre-
eclampsia is sFlt-1 (soluble FMS-like tyrosine kinase 1), an inhibitor of the
vascular growth factor VEGF (and the receptor – VEGFR1 - for it, when on
the cell membrane). It is likely that there is a link between complement,
vascular changes and sFlt-1 in preeclampsia. More on this, inflammation,
clearance and tolerance during pregnancy can be found in the paper by
Teirilä and her colleagues.
Apart from kidney diseases complement has traditionally been
considered to have a clear and significant role also in rheumatic dis-
eases. These are discussed in the article by Dijkstra and colleagues.
Early classical pathway deficiencies predispose to lupus (SLE, systemic
lupus erythematosus) and lupus-like disorders and excessive comple-
ment activation is seen in autoimmune diseases, like rheumatoid ar-
thritis. In a way, these diseases represent the two opposite mechanisms
of complement involvement. Thus, paradoxically, both complement
deficiency and overactivation can lead to arthritis, and other systemic
disease manifestations, like vasculitis. In rheumatoid arthritis comple-
ment is believed to become activated by immune complexes, like those
between rheumatoid factors and IgG, and by autoantibodies to ci-
trullinated or carbamylated molecules with neoantigenic properties.
Complement deficiency-related lupus is thought to be due to an in-
ability to remove debris from injured tissues or apoptotic/damaged
cells. Complement is needed for removal of chromatin complexes,
phospholipid-containing membrane fragments and immune complexes.
If the clearance fails, the material may accumulate in vessel walls and
lead to vasculitis and to secondary autoimmunity against e.g. DNA and
phospholipids. This model is supported e.g. by a similar disease related
to mutations in DNAse or anti-phospholipid antibody syndrome.
Recently, however, additional mechanisms related to abnormal activity
of T cells, CD8 + T cell metabolism or lack of tolerance in C1q defi-
ciency have also been proposed. The roles of complement dysregula-
tion, abnormal functions of FHRs, insufficient protection by factor H,
C4bp or by membrane regulators have received, however, relatively
little attention. The team of Leendert Trouw in their article will explore
both traditional and novel aspects to provide a balanced update of the
role of complement in rheumatoid arthritis, lupus and ANCA vasculitis.
A wide spectrum of functions of complement has been discovered in
the central nervous system (CNS). In their article on “Complement
dysregulation in the CNS” Lee et al describe not only the protective and
damaging complement functions but also the surprising activities in
brain development. For example, complement has been suggested to
have a role in synaptic pruning to prevent an excess of neuronal con-
nections in the limited space of the brain during its early development.
Assumingly, the pruning process of complement together with the brain
phagocytes, primarily microglia, is important for a proper function of
neuronal networks. Although not yet firmly documented, it is possible
that excess synaptic activities could predispose to schizophrenia later in
life. Other unexpected, and unbiased, observations suggest that com-
plement is involved in neuronal development, for example in guiding
neuronal migration and in promoting progenitor cell proliferation.
Another important role for complement is assumed to take place along
with aging, and related events in the brain. Atherosclerosis with all its
consequences, like stroke and brain hemorrhage, involves complement at
different disease stages, in the long period of disease development as well
as in the inflammatory responses to acute attacks. The mechanisms of
development of different forms of dementia, like a small vessel disease in
the brain or Alzheimer’s disease, are poorly understood. Changes in vas-
cular walls or accumulation of fibrillary material because of an inability to
prevent its formation or to clear it are thought to involve also the com-
plement system. Unsuccessful attempts by complement and phagocytes to
remove the waste material or protease-resistant fibrils may sustain pro-
longed inflammation and lead to neuronal damage. Trent Woodruff to-
gether with his colleagues provide an in-depth description of the current
state of understanding in this very fascinating area that will certainly raise
interest also outside the complement field.
Because complement is a central mechanism in causing inflamma-
tion and tissue damage, an intense effort is ongoing to develop suitable
pharmacological agents to control its excessive activation, to correct
misdirected attacks or even to use its enormous biological power for
treatment of malignant disease. Initial progress in these attempts has
already been made, but surely, more is to come.
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